Season Two of Surfing The NASH Tsunami

S2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?

S2-E57.4 – TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?

Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2020 TLMdX, the AASLD annual liver meeting. This conversation focuses on issues that will increase the richness of our understanding of disease and predictions for TLM 2022 (Hopefully not Digital only!)

S2-E57.1 - TLMdX 2021 from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

S2-E57.1 – 2021 TLMdX from AASLD: Putting a “Big, Fat Dent” in NAFLD and NASH

Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on, in the words of Stephen Harrison, “putting a big, fat dent in Fatty Liver disease.”

S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E56 – Day Four at the 2021 TLMdX From AASLD

Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD

S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities

S2-E54.3 – Inside the Patient-Focused Drug Development Meeting: The Advocates’ Priorities

Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green. They discussed the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021. This included the advocates’ priorities (both those who spoke in the PFDD session and others like our panelists) for changes in regulatory policy and programs.

S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint

S2-E52.4 – MRE Findings Suggest Flaws in Fibrosis As Endpoint

Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about the availability of subgroup analysis.

Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?

S2-E52.3 – Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?

Alina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial Endpoints from non-invasive testing data. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.

S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management

S2-E52.2 – How Liver Stiffness Measurements Can Improve Practical Patient Management

Alina Allen and Ian Rowe discuss how Liver Stiffness Measurements (LSM) can improve individual patient treatment in pre-cirrhotic and compensated cirrhotic patients. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about the availability of subgroup analysis.

Predicting long-Term Outcomes Using MR Elastography

S2-E52 – Predicting Long-Term Outcomes Using MR Elastography

Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic’s recent Hepatology publication, “MRE for prediction of long term progression and outcome in chronic liver disease.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud